Literature DB >> 19285573

Complement factors C3a and C5a have distinct hemodynamic effects in the rat.

Lavinia M Proctor1, Tyson A Moore, Peter N Monk, Sam D Sanderson, Stephen M Taylor, Trent M Woodruff.   

Abstract

In the rat, C5a infusion mediates well-defined effects including hypotension and neutropenia. Conversely, the comparative effect of C3a in the rat is not yet defined. In the current study, we have investigated C3a receptor (C3aR) activation in the rat, using recombinant human C3a, the C3aR agonist WWGKKYRASKLGLAR, which is a C-terminal analogue of C3a, and a nonpeptide C3aR antagonist SB-290157, as pharmacological tools. In vitro, C3a and WWGKKYRASKLGLAR selectively bound to C3aRs and induced degranulation of C3aR-transfected RBL-2H3 cells. C3a or WWGKKYRASKLGLAR-induced degranulation was dose-dependently antagonized in a surmountable fashion by the nonpeptide C3aR antagonist. Intravenous infusion of C3a and WWGKKYRASKLGLAR to rats induced a rapid, transient and concentration-dependent hypertensive response, which was mediated by C3aR-induced prostanoid release. C3a and WWGKKYRASKLGLAR caused a small drop in circulating neutrophils, but a rise in circulating neutrophils was evident after 90-120 min. In contrast to C3a, C5a infusion resulted in hypotension, and rapid and transient neutropenia. These results demonstrate that C3a and C5a mediate distinct effects on blood pressure and circulating polymorphonuclear leukocytes in the rat.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19285573     DOI: 10.1016/j.intimp.2009.03.002

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  11 in total

1.  Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats.

Authors:  Kathryn E Lillegard; Alex C Loeks-Johnson; Jonathan W Opacich; Jenna M Peterson; Ashley J Bauer; Barbara J Elmquist; Ronald R Regal; Jeffrey S Gilbert; Jean F Regal
Journal:  J Pharmacol Exp Ther       Date:  2014-08-22       Impact factor: 4.030

2.  De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation.

Authors:  Meghan L Bellows-Peterson; Ho Ki Fung; Christodoulos A Floudas; Chris A Kieslich; Li Zhang; Dimitrios Morikis; Kathryn J Wareham; Peter N Monk; Owen A Hawksworth; Trent M Woodruff
Journal:  J Med Chem       Date:  2012-04-20       Impact factor: 7.446

3.  Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts.

Authors:  Carl Atkinson; Bernhard Floerchinger; Fei Qiao; Sarah Casey; Tucker Williamson; Ellen Moseley; Serban Stoica; Martin Goddard; Xupeng Ge; Stefan G Tullius; Stephen Tomlinson
Journal:  Circulation       Date:  2013-02-26       Impact factor: 29.690

4.  Complement activation is critical for placental ischemia-induced hypertension in the rat.

Authors:  Kathryn E Lillegard; Alex C Johnson; Sarah J Lojovich; Ashley J Bauer; Henry C Marsh; Jeffrey S Gilbert; Jean F Regal
Journal:  Mol Immunol       Date:  2013-05-15       Impact factor: 4.407

Review 5.  Recent developments in low molecular weight complement inhibitors.

Authors:  Hongchang Qu; Daniel Ricklin; John D Lambris
Journal:  Mol Immunol       Date:  2009-10-02       Impact factor: 4.407

6.  Neutrophil Depletion Attenuates Placental Ischemia-Induced Hypertension in the Rat.

Authors:  Jean F Regal; Kathryn E Lillegard; Ashley J Bauer; Barbara J Elmquist; Alex C Loeks-Johnson; Jeffrey S Gilbert
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

7.  Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a.

Authors:  Rink-Jan Lohman; Johan K Hamidon; Robert C Reid; Jessica A Rowley; Mei-Kwan Yau; Maria A Halili; Daniel S Nielsen; Junxian Lim; Kai-Chen Wu; Zhixuan Loh; Anh Do; Jacky Y Suen; Abishek Iyer; David P Fairlie
Journal:  Nat Commun       Date:  2017-08-24       Impact factor: 14.919

8.  Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice.

Authors:  Erik Őrfi; Tamás Mészáros; Mark Hennies; Tamás Fülöp; László Dézsi; Alexander Nardocci; László Rosivall; Péter Hamar; Barry W Neun; Marina A Dobrovolskaia; János Szebeni; Gábor Szénási
Journal:  Int J Nanomedicine       Date:  2019-02-26

9.  Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy.

Authors:  László Dézsi; Tamás Mészáros; Erik Őrfi; Tamás G Fülöp; Mark Hennies; László Rosivall; Péter Hamar; János Szebeni; Gábor Szénási
Journal:  Molecules       Date:  2019-09-09       Impact factor: 4.411

10.  The "C3aR Antagonist" SB290157 is a Partial C5aR2 Agonist.

Authors:  Xaria X Li; Vinod Kumar; Richard J Clark; John D Lee; Trent M Woodruff
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.